中国银行公告，中国银行股份有限公司董事会于2026年3月3日召开会议，决定聘任黄学玲女士为本行副 行长。黄学玲女士，1977年出生，2026年加入本行。此前，她曾担任中央汇金投资有限责任公司股权管 理二部主任，资本运营部主任，兼中央汇金资产管理有限责任公司董事长、总经理等职务。黄学玲女士 的任职资格尚待国家金融监督管理总局核准。 ...

中煤能源公告称，公司股票在2026年2月27日、3月2日和3月3日连续3个交易日收盘价格涨跌幅偏离值累 计达20%，构成股票交易异常波动。经核查，公司目前日常经营及外部环境未发生重大变化，公司及控 股股东、实际控制人均不存在应披露而未披露的重大信息，未发现相关媒体报道、市场传闻，未涉及市 场热点概念，公司董高监及控股股东在此期间未买卖公司股票。 ...

黄学玲出生于1977年，2026年加入中国银行，获北京大学经济学硕士学位，拥有丰富的金融领域管理从 业经历。2025年7月至2026年2月，其任中央汇金投资有限责任公司股权管理二部主任；2020年4月至 2025年7月，任中央汇金投资有限责任公司资本运营部主任，兼中央汇金资产管理有限责任公司董事 长、总经理。此外，黄学玲还曾任中央汇金投资有限责任公司综合管理部副主任，中央汇金资产管理有 限责任公司执行董事，中国出口信用保险公司董事，中央汇金公司综合管理部╱银行机构管理二部改革 规划处主任等职务。 银行频道更多独家策划、专家专栏，免费查阅>> 责任编辑：钟离 3月3日，中国银行在北京召开董事会会议，会议审议并表决通过议案，聘任黄学玲为副行长，相关任职 资格待国家金融监督管理总局核准。 本次董事会会议以现场表决方式召开，会议通知于2026年2月25日通过书面及电子邮件方式送达全体董 事，由董事长葛海蛟主持。会议应出席董事16名，实际亲自出席16名，高级管理层成员列席会议。会议 的召开符合《中华人民共和国公司法》等相关法律法规、部门规章、规范性文件以及《中国银行股份有 限公司章程》的规定。此次聘任议案经记名投票表决 ...

Core Viewpoint - Despite achieving its first annual profit, BeiGene's stock price fell significantly after the earnings report, reflecting market concerns about growth quality and pipeline execution pace [1][14]. Financial Performance - In 2025, BeiGene reported a total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, with product revenue reaching 37.77 billion yuan, accounting for nearly 99% of total revenue [2][15]. - The company achieved a net profit attributable to shareholders of 1.422 billion yuan, marking a turnaround from a loss of 4.978 billion yuan in the previous year [2][16]. - The adjusted net profit was 1.381 billion yuan, a significant improvement from a loss of 5.379 billion yuan the previous year [2][16]. Product Performance - The star product, Bruton’s tyrosine kinase (BTK) inhibitor, achieved global sales of 28.067 billion yuan in 2025, a 48.8% increase, representing 73.8% of the company's product revenue [3][17]. - Sales in the U.S. reached 20.206 billion yuan, up 45.5%, while European sales surged 66.4% to 4.265 billion yuan, and Chinese sales grew 33.1% to 2.472 billion yuan [4][17]. Cost and Efficiency - The gross margin for products under GAAP increased to 87.3%, up from 84.3% the previous year, indicating improved cost control [5][18]. - Research and development expenses were 21.46 billion yuan, a 9.88% increase, while sales and management expenses were 20.81 billion yuan, up 13.65%, both growing slower than revenue [6][20]. Cash Flow and Assets - Free cash flow for 2025 was 9.42 billion yuan, a significant recovery from a negative cash flow of 6.33 billion yuan the previous year [7][20]. - Total assets reached 57.423 billion yuan, a 34.1% increase from the beginning of the year, driven by steady cash inflows from operations [7][20]. Market Concerns - The company provided a revenue guidance of 6.2 to 6.4 billion USD for 2026, indicating a slowdown to approximately 20% growth compared to 40% in 2025, raising concerns about future growth potential [8][21]. - The market is worried about the ability of the pipeline to deliver new growth, as the first wave of core products enters a mature growth phase [9][21]. Pipeline and Future Growth - The second-tier products are experiencing slower execution, with the BCL2 inhibitor expected to receive regulatory decisions in 2026, but large-scale commercialization will take time [10][22]. - Early-stage pipeline products are unlikely to generate significant revenue in the near term, leading to concerns about the sustainability of growth in the next few years [11][23].

Core Viewpoint - The strategic partnership between Alibaba Health and Meinian Health aims to enhance home nursing services through digital transformation in the healthcare sector, focusing on accessibility and user experience [1][2]. Group 1: Collaboration Details - The partnership will focus on three core areas: nursing service collaboration, operational integration, and business closure [2]. - Alibaba Health will connect with Meinian Health's professional nursing team to create a 30-minute health service circle, offering home services for chronic disease management, rehabilitation care, and post-operative dressing changes [2]. - Both companies will unify service standards through online and offline training, with Meinian Health providing exclusive benefits to Alibaba Health users [2]. Group 2: Resource Complementation - Alibaba Health is a leading internet healthcare platform with strong online service capabilities, leveraging user insights to match services for post-examination recovery, medication, and nursing needs [2][3]. - Meinian Health has served nearly 300 million people since its listing in 2015, conducting about 30 million health check-ups annually and maintaining nearly 600 offline health check centers, accumulating extensive multimodal health data [3]. - The collaboration aims to transform Meinian Health's capabilities from primarily serving health check scenarios to supporting home nursing services with critical medical data [3]. Group 3: Leadership Insights - Alibaba Health's CEO highlighted the impact of AI on information accessibility and the shift of some medical services from hospitals to home settings, indicating a growing user willingness for convenient healthcare solutions [3]. - Meinian Health's Chairman emphasized the partnership's goal to make professional health services more accessible and to transition the company into an AI-driven health management technology platform [3].

每经AI快讯，有投资者在投资者互动平台提问：请问公司与比亚迪公司有深度合作吗？如果有，请问 是哪些领域或项目？ 英杰电气（300820.SZ）3月3日在投资者互动平台表示，您好，公司子公司英杰新能源曾经通过比亚迪 公司向境外企业销售多媒体充电桩产品，近年来与比亚迪公司无直接业务合作，感谢您的关注。 （文章来源：每日经济新闻） ...

Core Insights - The competition landscape in China's new energy vehicle (NEV) market has become clearer as of early 2026, with BYD Group leading the industry with a sales volume of 190,190 units in February, maintaining a significant advantage over competitors [1][4]. Group 1: Sales Performance - BYD has maintained its position as the top seller in China's NEV market for 57 consecutive months since June 2021, with cumulative sales surpassing 15.5 million units [3]. - In February, BYD's overseas sales of passenger cars and pickups reached 100,151 units, marking a year-on-year growth of 41.4%, with total overseas sales for January-February 2026 at 200,160 units, up 42.3% year-on-year [4]. Group 2: Market Position and Strategy - BYD's strong performance in February signals its ability to build systemic advantages in the NEV market, indicating that its leadership is structural rather than coincidental [4]. - The company is set to hold a groundbreaking technology release on March 5, which has already positively impacted its stock price, reflecting investor confidence in its technological capabilities [5]. Group 3: High-End Market Development - BYD's high-end brands, including Fangchengbao, Tengshi, and Yangwang, achieved combined sales of 23,000 units in February, showing significant growth and enhancing the company's product structure and profitability [5]. - The increasing share of high-end products is expected to strengthen BYD's brand value and market influence [5]. Group 4: Future Considerations - Despite the positive outlook, BYD must focus on advancements in intelligent driving technology to compete effectively against rivals like Huawei and new entrants [5]. - The company faces challenges related to geopolitical risks as its overseas sales grow, including trade policies, tariff barriers, and localization requirements [5].

"比亚迪：感谢老伊刷的火箭……"某网友。 最近几天，汽车圈、科技圈甚至军事圈，都被一个极其离谱但真实的"新闻"，刷屏了。 一辆比亚迪元PLUS（海外叫ATTO 3），在以色列耶路撒冷，近距离"硬扛"了一发伊朗导弹。 你没看错，不是碰撞测试，是真实的战争场景。 导弹在旁边爆炸，炸出数米大坑，车辆外壳严重损毁，玻璃全碎。 但结果是： 车上5-6人全部生还，ABC柱没变形，车门能打开，最关键的——比亚迪招牌的刀片电池，没起火、没爆炸。 一时间，#比亚迪元plus贴身挨了一发导弹# 冲上热搜！ 网友封其为"公路坦克"，称之为"史上最硬核广告"、"诺基亚挡子弹的汽车版"。 由于现在AI太发达了，大叔一开始也以为，这是"假消息"。 我专门根据截图，求证了消息，确实有一家外媒做了报道。（但所有有关车的信息，报道并未提及，先画个重点，下面细说） 虽然比亚迪官方没有回应此事，但一位认证信息为"比亚迪王朝网销售事业部总经理 路天"转发了相关微博。 并附上一句"安全是最大的豪华！" 网友彻底沸腾了！！！ 大叔稍微研究了下这篇外媒报道，有几个细节，很有意思。 比如第一个细节是时间。 报道时间是：2026年3月1日晚上11点03分！ ...

Core Viewpoint - The 34th East China Import and Export Commodity Fair (referred to as "HuaJiaoHui") will be held from March 1 to 4, 2026, at the Shanghai New International Expo Center, with the Industrial and Commercial Bank of China (ICBC) Shanghai Branch actively supporting the event to promote Chinese brands internationally and contribute to the Belt and Road Initiative [1][3]. Group 1: Cross-Border Trade Facilitation - The procurement matchmaking event successfully connected nearly 30 overseas professional buyers with over 50 domestic foreign trade enterprises through both online and offline methods, facilitating deep cooperation and achieving multiple intended transaction results across various sectors such as consumer goods, daily necessities, and electronics [1][4]. Group 2: Tailored Services for Overseas Buyers - ICBC Shanghai Branch provided one-on-one exclusive guidance for overseas buyers, assisting them in identifying product needs and potential exhibitors, while also offering multilingual support for real-time translation during the event [2][5]. Group 3: Comprehensive Financial Services for Foreign Trade Enterprises - ICBC Shanghai Branch offered a range of financial services including international settlement, trade financing, and foreign exchange risk management, promoting policies for cross-border trade facilitation and new financial products to support Chinese foreign trade enterprises in the international market [3][7]. - The bank plans to enhance its cross-border financial service capabilities through strategic cooperation with government agencies, industry associations, and domestic and foreign enterprises, aiming to contribute to stabilizing foreign trade and promoting openness [7].

Group 1 - The core point of the announcement is the approval for China Galaxy Securities Co., Ltd. to provide primary market-making services for the Fuguo Money Market Fund starting from March 4, 2026 [1][2][3] - The decision aims to enhance the market liquidity and stable operation of the Fuguo Money Market Fund, as per the relevant regulations [1] - The fund is identified by its code 511900, and the announcement is part of the Shanghai Stock Exchange's efforts to regulate listed fund market-making activities [1]